The Sentinel


Wednesday, April 21, 2021

Letter from the Editor- April

Dear JITC Readers,

It is a pleasure to welcome you to this month’s JITC digest. The original research articles highlighted in this edition are fantastic examples of mechanistic insight interwoven with new strategies for intervention and vice versa—the seamless reverse translational cycle that is central to the immunotherapy field.
Novel targets for immunotherapy are characterized by Aiqin Gao and colleagues, who show that blocking ILT4 relieves T cell immunosenescence via ERK-dependent metabolic perturbations, as well as François Anna et al, who take aim at HLA-G with the first chimeric antigen receptor (CAR) T cells against the dual function tumor-specific antigen and immune checkpoint.
Esther Redin and colleagues demonstrate that inhibition of the SRC-family kinase YES1 with the approved leukemia drug dasatinib decreases CD4+ Treg conversion and enhances the efficacy of PD-1 blockade in non-small cell lung cancer.
Another strategy to augment the anti-tumor effects of PD-1 inhibition is identified by Yoke Seng Lee et al, who establish a link between conventional type 1 dendritic cell counts and responses to immunotherapy in patients with melanoma as well as in a novel humanized mouse model.

Finally, Gino M Dettorre and colleagues validate a readily available index of hyperinflammation incorporating lymphopenia and hypoalbuminemia that predicts outcomes of SARS-CoV-2 infection in patients with cancer—research that hints at interventions to prevent severe disease and nicely complements recently published articles in JITC’s ongoing COVID-19 and Cancer Immunotherapy Review Series.
Best regards,

Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer

To view the entire April 2021 JITC Digest, please click here

No comments:

Post a Comment